Nurix Therapeutics, Inc. — Form 10-Q Summary
Reporting period: The filing covers the quarter and six months ended May 31, 2024 (Nurix’s fiscal second quarter of 2024), compared with the same periods in 2023. The request metadata says “2023 Q2,” which does not match the filing period.
Business context and reporting period
Nurix is a clinical-stage biopharmaceutical company developing protein-degradation and protein-elevation medicines using its DELigase platform. Its wholly owned clinical programs include NX-5948 and NX-2127, BTK degraders, and NX-1607, a CBL-B inhibitor. Collaborations with Gilead, Sanofi and Pfizer (formerly Seagen) support partnered discovery programs. Nurix has no approved products and has not generated product-sale revenue.
Financial performance and position
| Metric | Three months ended May 31, 2024 | Six months ended May 31, 2024 |
|---|---|---|
| Total revenue | $12.1 million | $28.7 million |
| Research and development expense | $48.9 million | $98.9 million |
| General and administrative expense | $11.7 million | $23.5 million |
| Operating loss | $48.5 million | $93.8 million |
| Net loss | $44.5 million | $86.1 million |
| Net loss per share, basic and diluted | $0.71 | $1.47 |
| Operating cash used | Six-month total: $81.7 million |
Quarterly collaboration revenue was $12.1 million; there was no license revenue. Six-month revenue comprised $28.7 million of collaboration revenue. No product revenue or profitability was reported. Interest and other income was $4.1 million for the quarter and $7.9 million for the six months.
At May 31, 2024, cash and cash equivalents were $116.8 million, current marketable securities were $326.3 million, and non-current marketable securities were $9.4 million. Total assets were $511.0 million, current liabilities $80.8 million, total liabilities $140.3 million and stockholders’ equity $370.7 million. The filing reports no borrowings or debt. Current assets were about 5.6 times current liabilities.
Management states that cash, cash equivalents and short-term marketable securities of $443.1 million are sufficient to fund operations for at least 12 months after issuance of the statements. Elsewhere, MD&A reports $452.5 million of cash, cash equivalents and marketable securities, which includes non-current securities; the filing does not use the same liquidity measure consistently.
Material changes versus the prior comparable period
- Quarterly revenue fell $18.6 million year over year, primarily because the prior-year quarter included $20.0 million of Gilead license revenue. Collaboration revenue increased $1.4 million, including $5.2 million from Pfizer, partly offset by lower Sanofi and Gilead revenue.
- Six-month revenue declined $14.7 million to $28.7 million, again reflecting the absence of the prior-year $20.0 million license payment; collaboration revenue increased $5.3 million.
- Net loss widened to $44.5 million for the quarter from $24.3 million, and to $86.1 million for the six months from $65.0 million. R&D expense rose $3.2 million quarterly and $7.3 million year to date, including higher clinical, contract-manufacturing and facility costs.
- Operating cash use increased to $81.7 million for the six months from $66.9 million. Investing activities used $95.6 million, primarily reflecting purchases of marketable securities.
- Financing provided $239.4 million in the first six months, chiefly from the April public offering and May ATM sales. These transactions increased issued and outstanding common shares from 48.7 million at November 30, 2023 to 64.4 million at May 31, 2024.
Outlook, commentary, risks and unusual items
- Management expects continued losses and higher expenses as clinical trials, manufacturing, platform research and infrastructure advance. It says existing resources cover at least the next 12 months, but substantial additional funding will be needed to pursue the longer-term plan; future financing may dilute shareholders or require giving up program rights.
- Nurix received a $15.0 million Gilead payment for a two-year research-term extension in the second quarter. Sanofi extended the STAT6 research term by two years; the revised estimates produced a cumulative reduction in revenue recognized in the current period. Nurix achieved a $5.0 million Pfizer research milestone in May and expected payment in fiscal Q3 2024.
- NX-5948 is in a Phase 1a/1b study and received FDA Fast Track designation for specified relapsed or refractory CLL/SLL patients. NX-2127 is in Phase 1a/1b; the FDA lifted its partial clinical hold in March 2024, and Nurix planned to resume enrollment using a new chirally controlled drug substance. NX-1607 is in a Phase 1a/1b study.
- Key risks include early-stage clinical uncertainty and potential adverse effects, patient-enrollment and manufacturing delays, dependence on single-source suppliers and collaborators, competition, intellectual-property disputes, and the need for additional capital. The filing identifies a third-party patent that may be alleged to cover NX-5948 or NX-2127; Nurix says it believes it has valid defenses, but cannot assure the outcome.
- Nurix reported no material legal proceedings, no material changes in internal control over financial reporting, and effective disclosure controls as of May 31, 2024. Operating lease commitments were approximately $39.8 million, including $8.1 million expected within 12 months.
- After quarter-end, Nurix filed an automatic shelf registration statement in June and amended its ATM agreement on July 11, 2024, providing for up to $150.0 million of common-stock sales. These potential sales may dilute existing shareholders.
Most important facts for investors to verify
- Confirm the filing period: this is a quarter ended May 31, 2024, not Q2 2023.
- Reconcile the stated $443.1 million of cash and short-term securities with the $452.5 million figure that includes non-current marketable securities.
- Track clinical-trial progress, safety, enrollment and timing—especially NX-2127’s restart following the partial hold and drug-substance change.
- Assess the sustainability and timing of collaboration revenue, milestone receipts and the Sanofi STAT6 extension’s impact on revenue recognition.
- Monitor operating cash use, the stated 12-month funding outlook, and dilution from completed and potential equity offerings, including outstanding pre-funded warrants and the expanded ATM.
- Review developments in the third-party patent matter and Nurix’s ability to maintain intellectual-property protection and manufacturing supply.